[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510124":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":21,"collaborators":20,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":20,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":20,"studyType":36,"phases":37,"briefSummary":39,"conditions":40,"keywords":20,"overallStatus":42,"whyStopped":20,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":20},{"fullName":5,"class":6},"Fujian Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"hypersensitivity group","EXPERIMENTAL","Corresponding intervention measures are given for different levels of hypersensitivity reactions",[13],"Combination Product: Anti-allergic treatment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"COMBINATION_PRODUCT","Anti-allergic treatment","For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg\u002Fml, 0.1 mg\u002Fml and 5 mg\u002Fml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.\n\nGrade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.\n\nGrade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml\u002Fh\\*1h, 45ml\u002Fh\\*1h, then 225ml\u002Fh\\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml\u002Fh\\*0.5h, then 150ml\u002Fh\\*3 hours.",[9],null,{"type":22,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100510124","phase-2-phase-ii-study-of-reuse-of-oxaliplatin-hypersensitivity-in-gastrointestinal-tumors-100510124",false,"NCT05922358","Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors","Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Patients who plan to receive oxaliplatin treatment;\n2. Male or female aged 18-75 year;\n3. ECOG PS 0-2;\n4. The expected survival time is more than 3 months;\n5. Capable and willing to accept survey patients\n\nExclusion Criteria:\n\n1.Patients who were not suitable for the enrollment of this study judged by the investigator","ALL","18 Years","75 Years",{"count":34,"type":35},500,"ESTIMATED","INTERVENTIONAL",[38],"PHASE2","The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%. The purpose of this study is to prospectively investigate the incidence of oxaliplatin allergy and neurotoxicity, and to evaluate the use of effective anti-allergic and desensitization therapies to enable patients who are already allergic to oxaliplatin to complete their prescribed doses smoothly.",[41],"Gastrointestinal Tumors","NOT_YET_RECRUITING","2023-06-19",{"date":45,"type":46},"2023-06-28","ACTUAL",{"date":48,"type":35},"2023-09-01",{"date":50,"type":35},"2026-09-01",{"name":5,"class":6}]